Epidermal Growth Factor Receptor Gene and Protein and Gefitinib Sensitivity in Non–Small-Cell Lung Cancer
Ospedale Bellaria · University of Colorado Denver · +4 more institutions
Abstract
Gefitinib is a selective inhibitor of the epidermal growth factor (EGFR) tyrosine kinase, which is overexpressed in many cancers, including non-small-cell lung cancer (NSCLC). We carried out a clinical study to compare the relationship between EGFR gene copy number, EGFR protein expression, EGFR mutations, and Akt activation status as predictive markers for gefitinib therapy in advanced NSCLC.
Tumors from 102 NSCLC patients treated daily with 250 mg of gefitinib were evaluated for EGFR status by fluorescence in situ hybridization (FISH), DNA sequencing, and immunohistochemistry and for Akt activation status (phospho-Akt [P-Akt]) by immunohistochemistry. Time to progression, overall survival, and 95% confidence intervals (CIs) were calculated and evaluated by the Kaplan-Meier method; groups were compared using the log-rank test. Risk factors associated with survival were evaluated using Cox proportional hazards regression modeling and multivariable analysis. All statistical tests were two-sided.
Citation impact
- FWCI
- 147.38
- Percentile
- 100%
- References
- 47
Authors
20- FCFederico CappuzzoCorresponding
Ospedale Bellaria, University of Colorado Denver, San Raffaele University of Rome, Consorzio Interuniversitario Nazionale per l'Informatica, University of Colorado Cancer Center, University of Colorado Health
- FRFred R. Hirsch
Consorzio Interuniversitario Nazionale per l'Informatica, University of Colorado Health, University of Colorado Cancer Center, San Raffaele University of Rome, University of Colorado Denver, Ospedale Bellaria
- ERElisa Rossi
Ospedale Bellaria, San Raffaele University of Rome, University of Colorado Cancer Center, Consorzio Interuniversitario Nazionale per l'Informatica, University of Colorado Health, University of Colorado Denver
- SBStefania Bartolini
Consorzio Interuniversitario Nazionale per l'Informatica, University of Colorado Denver, San Raffaele University of Rome, University of Colorado Cancer Center, Ospedale Bellaria, University of Colorado Health
- GLGiovanni Luca Ceresoli
University of Colorado Health, University of Colorado Cancer Center, San Raffaele University of Rome, University of Colorado Denver, Consorzio Interuniversitario Nazionale per l'Informatica, Ospedale Bellaria
Topics & keywords
- Gefitinib
- Epidermal growth factor receptor
- Lung cancer
- Cancer research
- Gene
- Epidermal growth factor
- Biology
- Cancer